Nandrolone

Mechanism of Action

Nandrolone is an anabolic-androgenic steroid that exerts its effects primarily through interaction with androgen receptors. However, the specific molecular mechanisms and physiological pathways are not well-detailed in the provided evidence.

The available studies focus primarily on nandrolone's adverse effects and therapeutic applications rather than its core mechanism of action. Research shows that nandrolone decanoate can cause liver injury, as demonstrated in rat studies examining protective effects of cumin oil against nandrolone-induced hepatotoxicity. Additionally, prepubertal exposure to nandrolone affects testicular development, altering histological structure and spermatogenic processes in male mice, suggesting significant effects on reproductive tissue development.

One study investigated whether supraphysiological androgen administration (which would include compounds like nandrolone) provides additive benefits on hippocampal plasticity-related markers and behavior in male mice, though specific mechanistic details were not provided in the available abstracts.

Current clinical investigations are exploring nandrolone's therapeutic potential in sarcopenia treatment and cancer-related malnutrition, suggesting the compound may influence muscle protein synthesis and metabolic pathways, though the precise molecular mechanisms underlying these effects are not elaborated in the provided evidence.

Evidence Limitation: The provided research abstracts do not contain detailed information about nandrolone's specific molecular mechanism of action, receptor binding characteristics, or downstream signaling pathways. More comprehensive mechanistic studies would be needed to fully characterize how nandrolone works at the cellular and molecular level.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.

Nandrolone is being investigated for several therapeutic applications, though clinical evidence remains limited and findings are mixed.

Sarcopenia and Muscle Wasting

The most established clinical use of nandrolone is for sarcopenia treatment. One ongoing Phase 2 trial (NCT05978206) is evaluating nandrolone combined with physiotherapy and dietary interventions for sarcopenia management. The anabolic properties of nandrolone may help preserve or restore muscle mass in patients experiencing age-related or disease-related muscle loss.

Cancer-Related Malnutrition

Nandrolone has been studied for treating malnutrition in cancer patients. A completed clinical trial (NCT03263520) investigated its impact on cancer-induced malnutrition, though specific outcomes from this study are not detailed in the available evidence. The rationale likely stems from nandrolone's potential to stimulate appetite and promote weight gain in wasting conditions.

Telomeropathies

An interesting application emerged from a completed Phase 1/2 trial (NCT02055456) examining nandrolone decanoate for treating telomeropathies - rare genetic disorders affecting telomere function. This represents a novel therapeutic approach, though the mechanism and efficacy data are not provided in the current evidence.

Safety Considerations

Available research highlights several safety concerns:

• Liver toxicity: Animal studies demonstrate that nandrolone decanoate can cause liver injury, though protective effects of certain compounds (like cumin oil) have been investigated
• Reproductive effects: Prepubertal exposure studies in animals show alterations in testicular structure and spermatogenic function
• Neurological effects: Research suggests supraphysiological doses may not provide additional benefits for brain plasticity markers

Evidence Limitations

The clinical evidence for nandrolone remains limited. Most therapeutic applications are still in early-phase trials or have completed studies without published results. The available research consists primarily of animal studies and case reports rather than large-scale human clinical trials. Healthcare providers should carefully weigh potential benefits against documented risks when considering nandrolone therapy.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any nandrolone-based treatment.

The safety evidence for nandrolone is limited, with most available data coming from preclinical studies and small clinical trials. Healthcare providers should exercise caution when prescribing this medication due to insufficient comprehensive safety data.

Known Side Effects

Hepatic Effects
Preclinical studies indicate potential liver toxicity. One animal study documented nandrolone decanoate-induced liver injury in rats, though the clinical relevance to human dosing remains unclear.

Reproductive System Effects
Animal studies suggest significant reproductive toxicity:

• Prepubertal exposure in male mice caused alterations in testicular histological structure and disrupted spermatogenic dynamics
• These findings raise concerns about potential fertility impacts, though human data is lacking

Neurological Effects
Limited evidence suggests nandrolone may not provide expected benefits on hippocampal function and behavior, contrary to some theoretical expectations about anabolic steroids and brain function.

Contraindications and Populations That Should Avoid Nandrolone

Evidence is extremely thin regarding specific contraindications. Based on the available preclinical data, the following populations should exercise particular caution:

• Pediatric patients: Animal studies showing testicular damage with prepubertal exposure suggest avoiding use in children and adolescents
• Patients with liver disease: Given evidence of hepatotoxicity in animal models
• Men concerned about fertility: Due to potential reproductive system impacts observed in animal studies

Drug Interactions

No specific drug interaction data was identified in the available evidence. This represents a significant knowledge gap requiring further research.

Special Considerations

The current evidence base is heavily weighted toward animal studies, with very limited human safety data from completed clinical trials. Most ongoing trials are small-scale studies focusing on specific conditions (sarcopenia, cancer-related malnutrition, telomeropathies) rather than comprehensive safety assessment.

Clinical Note: This safety profile is based on extremely limited evidence. The lack of robust human safety data represents a significant concern for clinical use.

---

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Patients should consult their healthcare provider before starting, stopping, or changing any medication regimen.

Research Papers and Clinical Trials

Research on nandrolone has focused on several distinct areas, with studies examining both therapeutic applications and potential adverse effects.

Preclinical Studies

Recent animal research has investigated nandrolone's effects on various organ systems. A 2026 study in the Journal of Molecular Histology examined protective effects of cumin oil against nandrolone decanoate-induced liver injury in rats, suggesting potential hepatotoxic effects of the compound. Another 2026 study published in Clinical and Experimental Reproductive Medicine evaluated prepubertal exposure to nandrolone combined with royal jelly in male mice, finding alterations in testicular structure and sperm production through histomorphometric analysis.

A behavioral study in Hormones and Behavior (2026) examined whether supraphysiological androgen administration, including nandrolone, provided additional benefits for brain plasticity markers and behavior in untrained male mice. The research found no additive benefits beyond physiological levels.

Clinical Trials

Several clinical trials have explored nandrolone's therapeutic potential:

Sarcopenia Treatment: A Phase 2 trial (NCT05978206) is currently recruiting participants to study nandrolone's effectiveness for sarcopenia treatment when combined with physiotherapy and dietary interventions.

Telomeropathies: A completed Phase 1/2 trial (NCT02055456) investigated nandrolone decanoate for treating telomeropathies, though detailed results are not provided in the available evidence.

Cancer-Related Malnutrition: A completed study (NCT03263520) examined nandrolone's impact on cancer-induced malnutrition, though the phase designation was not specified.

Performance Enhancement: An ongoing invitation-only study (NCT07568574) is examining medically supervised performance-enhancing substances, including nandrolone, in elite athletes.

Evidence Limitations

The available evidence is limited by the small number of completed studies with published results. Most clinical trials listed are either still recruiting participants or have completed enrollment without detailed outcome data available. The preclinical studies, while informative about potential mechanisms and effects, are conducted in animal models and may not directly translate to human applications.

This information is for educational purposes only and should not be considered personalized medical advice. Consult with a healthcare provider for medical decisions.

Protocols

The available clinical evidence for nandrolone dosing protocols is limited, with most specific dosing information coming from a small number of clinical trials and research studies.

Clinical Trial Protocols

Sarcopenia Treatment (NCT05978206)
This ongoing Phase 2 trial is investigating nandrolone for sarcopenia treatment in combination with physiotherapy and diet modifications, though specific dosing details are not available from the trial registry.

Telomeropathy Treatment (NCT02055456)
A completed Phase 1/2 trial examined nandrolone decanoate for treating telomeropathies, but detailed protocol information is not provided in the available evidence.

Cancer-Related Malnutrition (NCT03263520)
A completed trial investigated nandrolone's impact on cancer-induced malnutrition, though specific dosing protocols are not detailed in the available registry information.

Research Context

The available literature primarily focuses on nandrolone's effects in research settings, including studies examining liver toxicity, reproductive effects, and neurological impacts in animal models. However, these studies do not provide clinically applicable human dosing protocols.

Evidence Limitations

The current evidence base lacks comprehensive, published dosing protocols for nandrolone in clinical applications. Most available studies are either ongoing trials with unpublished protocols or completed studies without detailed dosing information in the public records.

---

Important Disclaimer: This information is for educational purposes only and should not be considered personalized medical advice. Nandrolone is a controlled substance in many jurisdictions and should only be used under direct medical supervision. Any treatment decisions should be made in consultation with qualified healthcare providers who can assess individual medical conditions, contraindications, and appropriate monitoring requirements.

Outcomes Summary for Nandrolone

The available evidence on nandrolone outcomes is limited and primarily derived from small clinical trials and preclinical studies. The strength of evidence is weak to moderate at best, with most human studies being early-phase trials with limited sample sizes.

Clinical Outcomes

Sarcopenia Treatment: One phase 2 trial (NCT05978206) is currently recruiting participants to evaluate nandrolone's effectiveness in treating sarcopenia when combined with physiotherapy and dietary interventions. Results are not yet available.

Telomeropathies: A completed phase 1/2 trial (NCT02055456) investigated nandrolone decanoate for treating telomeropathies, though specific outcomes data from this study are not provided in the available evidence.

Cancer-Related Malnutrition: One completed study (NCT03263520) examined nandrolone's impact on cancer-induced malnutrition, but outcome measures and results are not detailed in the available evidence.

Preclinical Findings

Animal studies suggest several concerning effects:

• Liver toxicity: Research in rats indicates nandrolone decanoate can cause liver injury, though protective effects of certain compounds (cumin oil) have been investigated
• Reproductive effects: Studies in male mice show that prepubertal nandrolone exposure can alter testicular structure and spermatogenic function
• Neurological effects: In previously untrained male mice, supraphysiological androgen doses (including nandrolone-related compounds) did not provide additional benefits for hippocampal plasticity markers or behavior

Evidence Limitations

The current evidence base has significant limitations:

• Most human trials are early-phase with no published outcome data available
• Sample sizes appear small based on trial descriptions
• Long-term safety and efficacy data are lacking
• Most available research focuses on adverse effects rather than therapeutic benefits

Disclaimer: This summary is for informational purposes only and should not be considered medical advice. Any decisions regarding nandrolone use should be made in consultation with qualified healthcare professionals who can evaluate individual circumstances and current clinical evidence.

The evidence suggests potential therapeutic applications for nandrolone in specific conditions, but robust clinical data supporting its efficacy and safety profile remain limited.